Loading...
XNAS
ASBPW
Market cap95mUSD
Oct 02, Last price  
0.01USD
Name

Aspire Biopharma Holdings Inc

Chart & performance

D1W1MN
XNAS:ASBPW chart

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

Key people

Executive Chairman of the Board, Chief Executive Officer · since 2023
Michael Howe
Chief Executive Officer, Director · since 2025
Ernest Scheidemann
Chief Financial Officer · since 2022
Kraig Higginson
Executive Chairman of the Board · since 2025
Surendra Ajarapu
Director · since 2023
Chief Financial Officer, Director · since 2025
Edward Kimball
Director
Edward Kimball
Director
Barbara Sher
Director
Independent Director · since 2023
Avinash Wadhwani
Independent Director · since 2023
URL
IPO date
Feb 18, 2022
Employees
Domiciled in
PR
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT